TipRanks
Prestige Consumer Healthcare (PBH)
NYSE:PBH
Want to see PBH full AI Analyst Report?

Prestige Consumer Healthcare (PBH) Price & Analysis

124 Followers

PBH Stock Chart & Stats

$51.21
$1.32(2.62%)
At close: 4:00 PM EDT
$51.21
$1.32(2.62%)

Bulls Say, Bears Say

Bulls Say
Acquisition-Led GrowthBreathe Right and LaCorium materially expand Prestige’s revenue base while adding exposure to respiratory and therapeutic skincare categories. Their expected accretion and integration through existing systems could improve scale, distribution leverage, and long-term earnings growth.
Strong Free Cash FlowRobust free cash flow provides internal funding for debt reduction, marketing, acquisitions, and operating investment. High cash conversion strengthens financial flexibility and supports the company’s ability to integrate brands while maintaining its broader growth strategy.
Profitable Diversified PortfolioPrestige’s broad branded OTC portfolio addresses recurring consumer health needs across multiple categories and channels. This diversification can reduce dependence on any single product, support retailer relevance, and provide a platform for marketing and distribution efficiencies.
Bears Say
Meaningful Leverage CostsMeaningful leverage and higher interest expense can absorb a substantial portion of operating cash flow, limiting flexibility for further acquisitions, marketing, or shareholder returns. Debt reduction and successful integration remain important to preserving financial resilience.
Modest Organic GrowthAcquisitions are carrying much of the near-term reported growth outlook, while underlying organic expansion remains modest. Limited core growth may constrain operating leverage and make future performance more dependent on successful brand investment and acquisition execution.
Supply And Margin PressureMulti-quarter supply variability and weaker gross margin can pressure product availability, revenue realization, and profitability. Although Clear Eyes is under 3% of sales, continued execution issues alongside transportation costs could weigh on margins during the integration period.

Prestige Consumer Healthcare News

PBH FAQ

What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was $42.62 and its highest was $71.07 in the past 12 months.
    What is Prestige Consumer Healthcare’s market cap?
    Prestige Consumer Healthcare’s market cap is $2.34B.
      When is Prestige Consumer Healthcare’s upcoming earnings report date?
      Prestige Consumer Healthcare’s upcoming earnings report date is Nov 05, 2026 which is in 12 days.
        How were Prestige Consumer Healthcare’s earnings last quarter?
        Prestige Consumer Healthcare released its earnings results on Aug 06, 2026. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.894 by $0.086.
          Is Prestige Consumer Healthcare overvalued?
          According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Prestige Consumer Healthcare pay dividends?
            Prestige Consumer Healthcare pays a Notavailable dividend of $0.475 which represents an annual dividend yield of 1.25%. See more information on Prestige Consumer Healthcare dividends here
              What is Prestige Consumer Healthcare’s EPS estimate?
              Prestige Consumer Healthcare’s EPS estimate is 1.07.
                How many shares outstanding does Prestige Consumer Healthcare have?
                Prestige Consumer Healthcare has 47,374,523 shares outstanding.
                  What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
                  Prestige Consumer Healthcare reported an EPS of $0.98 in its last earnings report, beating expectations of $0.894. Following the earnings report the stock price went up 2.737%.
                    Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
                    Currently, no hedge funds are holding shares in PBH
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      Prestige Consumer Healthcare

                      Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.

                      Prestige Consumer Healthcare (PBH) Earnings & Revenues

                      PBH Company Deck

                      PBH Earnings Call

                      Q1 2026
                      0:00 / 0:00
                      Earnings Call Sentiment|Positive
                      The call communicated a broadly positive operational and financial start to fiscal '27: reported revenue and adjusted EBITDA grew, record adjusted free cash flow was delivered, and two strategic acquisitions (Breathe Right and LaCorium) were closed and are expected to meaningfully expand revenue and margins. Management acknowledged notable near-term challenges — most prominently Clear Eyes supply variability from Pillar5 integration, YoY gross margin pressure from transportation costs, international distributor timing, and elevated debt/interest costs — but provided specific remediation and integration plans, maintained organic growth guidance (1%–3%) and raised reported guidance driven by acquisitions. Given the strong cash flow, completed integration of Breathe Right, accretive acquisition profile, and maintained outlook despite manageable headwinds, the overall tone and expected trajectory are positive.View all PBH earnings summaries

                      PBH Stock 12 Month Forecast

                      Average Price Target

                      $72.00
                      ▲(40.60% Upside)
                      {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"$43","58":"$58","73":"$73","50.5":"$50.5","65.5":"$65.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$72.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$72.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$72.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,50.5,58,65.5,73],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.77,46.86461538461539,48.95923076923077,51.05384615384616,53.14846153846154,55.24307692307693,57.33769230769231,59.432307692307695,61.52692307692308,63.621538461538464,65.71615384615384,67.81076923076924,69.90538461538462,{"y":72,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.77,46.86461538461539,48.95923076923077,51.05384615384616,53.14846153846154,55.24307692307693,57.33769230769231,59.432307692307695,61.52692307692308,63.621538461538464,65.71615384615384,67.81076923076924,69.90538461538462,{"y":72,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.77,46.86461538461539,48.95923076923077,51.05384615384616,53.14846153846154,55.24307692307693,57.33769230769231,59.432307692307695,61.52692307692308,63.621538461538464,65.71615384615384,67.81076923076924,69.90538461538462,{"y":72,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.93,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.69,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.44,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.53,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.68,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.09,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.95,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.16,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.22,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.64,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.77,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      SCYNEXIS
                      ―
                      ―
                      Cosmos Holdings
                      ―
                      ―
                      Biofrontera
                      ―
                      ―
                      Nasus Pharma Ltd.
                      ―
                      ―
                      Clinuvel Pharmaceuticals Limited Sponsored ADR
                      ―
                      ―

                      Ownership Overview

                      1.38%46.33%1.14%18.58%
                      1.14% Other Institutional Investors
                      18.58% Public Companies and
                      Individual Investors
                      Popular Stocks